Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2006-11-07
2009-10-20
Ouspenski, Ilia (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S387300
Reexamination Certificate
active
07605229
ABSTRACT:
The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases.
REFERENCES:
patent: 5364934 (1994-11-01), Drayna et al.
patent: 6569992 (2003-05-01), LaFleur et al.
patent: 7153950 (2006-12-01), Clark et al.
patent: 2004/0175380 (2004-09-01), Allison et al.
patent: 2005/0272118 (2005-12-01), Clark et al.
patent: 1 033 401 (2000-09-01), None
patent: 2001-269182 (2001-10-01), None
patent: 2002-502589 (2002-01-01), None
patent: WO 99/40100 (1999-08-01), None
patent: WO 01/10482 (2001-02-01), None
patent: WO 01/75166 (2001-10-01), None
patent: 02/070706 (2002-09-01), None
patent: WO 02/072794 (2002-09-01), None
patent: 2004/039394 (2004-05-01), None
patent: 2004/101756 (2004-11-01), None
patent: 2005/113003 (2005-12-01), None
patent: 2006/054961 (2006-05-01), None
patent: 2006/063067 (2006-06-01), None
patent: 2007/001459 (2007-01-01), None
Altschul and Gish, “Local Alignment Statistics”Methods in Enzymology266:460-480 (1996).
Attwood, Teresa K., “The Babel of Bioinformatics”Science290:471-473 (2000).
Bolton, C.,, “Recent advances in the pharmacological control of experimental allergic encephalomyelitis (EAE) and the implications for multiple sclerosis treatment”Multiple Sclerosis. 1:143-149 (1995).
Coligan et al., “Proliferative Assays for T Cell Function”Current Protocols in Immunology, John Wiley & Sons, Inc., Chapter 3.12, vol. 1 (1991).
Metzler et al., “Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28”Nature Structural Biol. 4(7):527-531 (Jul. 1997).
Skolnick et al., “From Genes to protein structure and function: novel applications of computational approaches in the genomic era”Trends in Biotechnology18(1):34-39 (Jan. 2000).
Carfi et al., “Herpes Simplex Virus Glycoprotein D Bound to the Human Receptor HveA”Molecular Cell8:169-179 (Jul. 2001).
Chen et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen”Journal of Molecular Biology293(4):865-881 (1999).
Cheung et al., “Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway”Proc. Natl. Acad. Sci. USA102:13218-13223 (2005).
Compaan et al., “Attenuating Lymphocyte Activity, The Crystal Structure of the BTLA-HVEM Complex”The Journal of Biological Chemistry280:39553-39561 (2005).
Croft, Michael, “The evolving crosstalk between co-stimulatory and co-inhibitory receptors: HVEM-BTLA”Trends in Immunology26:292-294 (2005).
Deppong et al, “Cutting Edge: B and T Lymphocyte Attenuator are Programmed Death Receptor-1 Inhibitory Receptors are Required for Termination of Acute Allergic Airway Inflammation”Journal of Immunology176:3909-3913 (2006).
Gavrieli et al., “BTLA and HVEM Cross Talk Regulates Inhibition and Costimulation”Advances in Immunology92:157-185 (2006).
Hakim et al., “Animal Models of Acute and Chronic Graft-Versus-Host Disease”Current Protocols in Immunology(unit 4.3, supplement 27), J E Coligan, A M Kruisbeek, D H Marglies, E M Shev, John Wiley & Sons, Inc (1998).
Hurchla et al, “B and T Lymphocyte Attenuator Exhibits Structural and Expression Polymorphisms and Is Highly Induced in Anergic CD4+ T Cells”Journal of Immunology174:3377-3385 (2005).
Marsters et al., “Identification of a Ligand for the Death-Domain-Containing Receptor Apo3”Current Biology8(9):525-528(1998).
Mauri et al., “LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator”Immunity8(1):21-30 (Jan. 1998).
Milne et al., “Function of Herpes Simplex Virus Type 1 gD Mutants with Different Receptor-Binding Affinities in Virus Entry and Fusion”Journal of Virology77(16):8962-8972 (Aug. 2003).
Montgomery et al., “Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family”Cell87(3):427-436 (1996).
Murphy et al., “Balancing co-stimulation and inhibition with BTLA and HVEM”Nature Reviews/Immunology6:671-681 (2006).
Sagawa et al., “The Protein-tyrosine Phosphatase SHP-2 Associates with Tyrosine-Phosphorylated Adhesion Molecule PECAM-1 (CD31)”Journal of Biological Chemistry272(49):31086-31091 (Dec. 5, 1997).
Sarrias et al., “The Three HveA Receptor Ligands, gD, Lt-α and LIGHT Bind to Distinct Sites on HveA”Molecular Immunology37:665-673 (2000).
Sedy et al., “B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator”Nature Immunology6:90-98 (2005).
Tao et al., “Differential Effects of B and T Lymphocyte Attenuator and Programmed Death-1 on Acceptance of Partially versus Fully MHC-Mismatched Cardiac Allografts”Journal of Immunology175:5774-5782 (2005).
Williams et al., “The immunoglobulin superfamily—domains for cell surface recognition”Ann. Rev. Immunol. 6:381-405 (1988).
Gonzalez et al., “A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator”Proc. Natl. Acad. Sci. USA102:1116-1121 (2005).
Watanabe N., et al.,, “BTLA is a Lymphocyte Inhibitory Receptor with Similarities to CTLA-4 and PD-1”Nature Immunology4(7):670-679 (Jul. 2003).
Costello et al, “Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity”Leukemia17:2500-2507 (2003).
Notice of Rejection (translation) mailed Nov. 13, 2008, in JP Application No. 2004-548251.
PCT International Search Report and Written Opinion of the International Searching Authority, mailed Nov. 7, 2008, for PCT International Application No. PCT/US2008/056765, filed Mar. 13, 2008.
Clark Hilary
Eaton Daniel L.
Gurney Austin L.
Wranik Bernd
Genentech Inc.
Ouspenski Ilia
Pasqualone Danielle M.
LandOfFree
PRO87299 polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PRO87299 polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PRO87299 polypeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4107072